BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

884 related articles for article (PubMed ID: 11713765)

  • 1. Gene therapy for hemophilia.
    Lynch CM
    Curr Opin Mol Ther; 1999 Aug; 1(4):493-9. PubMed ID: 11713765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene therapy strategies for hemophilia: benefits versus risks.
    Petrus I; Chuah M; VandenDriessche T
    J Gene Med; 2010 Oct; 12(10):797-809. PubMed ID: 20848668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
    High KA
    Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
    Kay MA; Manno CS; Ragni MV; Larson PJ; Couto LB; McClelland A; Glader B; Chew AJ; Tai SJ; Herzog RW; Arruda V; Johnson F; Scallan C; Skarsgard E; Flake AW; High KA
    Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
    Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
    Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene therapy for hemophilia.
    Chuah MK; Collen D; VandenDriessche T
    J Gene Med; 2001; 3(1):3-20. PubMed ID: 11269333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
    Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
    Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent expression of canine factor IX in hemophilia B canines.
    Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
    Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.
    Snyder RO; Miao C; Meuse L; Tubb J; Donahue BA; Lin HF; Stafford DW; Patel S; Thompson AR; Nichols T; Read MS; Bellinger DA; Brinkhous KM; Kay MA
    Nat Med; 1999 Jan; 5(1):64-70. PubMed ID: 9883841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene transfer as an approach to treating hemophilia.
    High KA
    Semin Thromb Hemost; 2003 Feb; 29(1):107-20. PubMed ID: 12640573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects.
    Hasbrouck NC; High KA
    Gene Ther; 2008 Jun; 15(11):870-5. PubMed ID: 18432276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical gene therapy studies for hemophilia using adeno-associated virus (AAV) vectors.
    Couto LB
    Semin Thromb Hemost; 2004 Apr; 30(2):161-71. PubMed ID: 15118928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical gene therapy studies for hemophilia using adenoviral vectors.
    Thorrez L; VandenDriessche T; Collen D; Chuah MK
    Semin Thromb Hemost; 2004 Apr; 30(2):173-83. PubMed ID: 15118929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and clinical gene therapy for haemophilia.
    Chuah MK; Collen D; Vandendriessche T
    Haemophilia; 2004 Oct; 10 Suppl 4():119-25. PubMed ID: 15479384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular genetics of hemophilia A].
    De Brasi CD; Slavutsky IR; Larripa IB
    Medicina (B Aires); 1996; 56(5 Pt 1):509-17. PubMed ID: 9239887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy for hemophilia: clinical trials and technical tribulations.
    Viiala NO; Larsen SR; Rasko JE
    Semin Thromb Hemost; 2009 Feb; 35(1):81-92. PubMed ID: 19308896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preparation of rAAV2/hFIX and experimentally application to gene therapy for hemophilia B].
    Peng JQ; Dong XY; Peng M; Chen L; Tan SP; Yuan H; Chen FP; Xue JL; Wu XB
    Zhonghua Xue Ye Xue Za Zhi; 2004 Sep; 25(9):513-8. PubMed ID: 15569526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy for hemophilia "A" and "B": efficacy, safety and immune consequences.
    Chuah M; Vandendriessche T
    Verh K Acad Geneeskd Belg; 2007; 69(5-6):315-34. PubMed ID: 18351211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy for hemophilia.
    Ponder KP
    Curr Opin Hematol; 2006 Sep; 13(5):301-7. PubMed ID: 16888433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AAV-mediated gene therapy for hemophilia.
    Couto LB; Pierce GF
    Curr Opin Mol Ther; 2003 Oct; 5(5):517-23. PubMed ID: 14601521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.